Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease
Romain Lécuyer(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Nahéma Issa(Bordeaux Population Health), Emmanuel Canet(Centre Hospitalier Universitaire de Nantes), Marie Gousseff(Centre hospitalier Bretagne Atlantique), Benjamin Gaborit(Inserm), Rose‐Anne Lavergne(Centre d'Investigation Clinique de Nantes), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), Fabrice Camou(Hôpital Saint-André), Anne Cady(Centre hospitalier Bretagne Atlantique), Florent Morio(Centre Hospitalier Universitaire de Nantes), Frederic Gabriel(Centre Hospitalier Universitaire de Bordeaux), F. Raffi(Inserm), Yoann Crabol(Centre hospitalier Bretagne Atlantique), David Boutoille(Inserm), A. Néel(Inserm)
Cited by 49
Related Papers
Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)
|The Lancet|2017|568
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study
|Intensive Care Medicine|2017|309
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2023|106
Severe varicella-zoster virus pneumonia: a multicenter cohort study
|Critical Care|2017|87